GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » Cyclically Adjusted PB Ratio

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Salarius Pharmaceuticals's current share price is $0.4951. Salarius Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 was $903.14. Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

SLRX's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Salarius Pharmaceuticals's adjusted book value per share data of for the fiscal year that ended in Dec23 was $1.342. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $903.14 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Salarius Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Salarius Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Salarius Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Salarius Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.4951/903.14
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Salarius Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Salarius Pharmaceuticals's adjusted Book Value per Share data for the fiscal year that ended in Dec23 was:

Adj_Book=Book Value per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=1.342/129.4194*129.4194
=1.342

Current CPI (Dec23) = 129.4194.

Salarius Pharmaceuticals Annual Data

Book Value per Share CPI Adj_Book
201412 -240.103 99.070 -313.658
201512 3,659.865 99.792 4,746.429
201612 2,210.022 101.863 2,807.895
201712 1,021.980 104.011 1,271.634
201812 321.100 105.998 392.051
201912 58.637 108.420 69.994
202012 23.268 109.897 27.401
202112 21.398 117.630 23.543
202212 4.603 125.222 4.757
202312 1.342 129.419 1.342

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Salarius Pharmaceuticals  (NAS:SLRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Salarius Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Executives
Tess Burleson director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber director C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar director C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum officer: Exec VP Finance, Interim CFO 3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur director, officer: Chief Executive Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan officer: Chief Financial Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr. director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang officer: Controller 2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers director 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc. 10 percent owner 75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal 10 percent owner C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p. 10 percent owner 800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Headlines

From GuruFocus

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

By Value_Insider Value_Insider 10-14-2022